Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel and Gefitinib in Elderly Patients With Advanced NSCLC
NCT00231465Phase 2Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Jul 2003
- Primary completion
- Aug 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gefitinib in non-small cell lung cancer (NSCLC), sponsored by Moffitt Cancer Center. Primary endpoint: Overall Response Rate at 19 months. Started Jul 2003; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00231465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00231465.